# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Andrea Tan downgrades Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Sell and lowers the price tar...
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of ...
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate o...
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates thei...